STI571 ProspectIve RandomIzed Trial: SPIRIT

Sponsor

Poitiers University Hospital (Other)

Overall Status

Completed

CT.gov ID

NCT00219739

Collaborator

Ministry of Health, France (Other), Novartis (Industry), Roche Pharma AG (Industry)

789

Enrollment

Location

Arms

135

Duration (Months)

5.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To test whether increasing the dose of imatinib or combining it with IFNalpha or ara-C increases the rate of molecular response (as measured by the decrease in BCR-ABL transcripts after 12 months of treatment) in patients with previously untreated CML in chronic phase.

To compare overall survival in a selected arm according to molecular response at 1 year from randomization with the reference arm.

Condition or Disease	Intervention/Treatment	Phase
Chronic Myeloid Leukemia	Drug: Imatinib mesylate 400 mg Drug: Imatinib mesylate 600 mg Drug: Imatinib 400 mg + Peg-Interferon Drug: Imatinib mesylate 400 mg + Cytarabine	Phase 3

Detailed Description

Imatinib at 400 mg daily has emerged as the preferred therapy for newly diagnosed CML patients who do not undergo allogeneic stem cell transplant.

A phase III randomized study, comparing imatinib at 400 mg per day to interferon plus cytarabine in newly diagnosed chronic phase CML patients enrolled 1106 patients from June 2000 to January 2001. 553 patients were randomized to each treatment. For comparative purposes, at 6 months, 75% of patients randomized to imatinib obtained a major cytogenetic response with 51% complete responses. Despite these impressive results, only a minority of patients treated with imatinib in this study achieved a molecular remission. When analyzed by log reduction in Bcr-Abl transcript levels using quantitative RT-PCR, 39% of patients achieved a 3-log reduction in Bcr-Abl levels, but only 13% and 3% achieved a 4- and 5-log reduction, respectively.2 To improve upon these results, various groups have tried higher doses of imatinib, and combinations of imatinib with interferon alpha or cytarabine. Each of these studies has used cytogenetic responses as the major endpoint.

Each of these therapies has increased toxicity as compared to 400 mg of imatinib alone and the rates of molecular remissions have not been reported.

Thus the purpose of this study is to first determine whether higher doses of imatinib or combining Imatinib with interferon or Ara-C would result in higher rates of molecular responses and if so, in better survival.

Study Design

Study Type:

Interventional

Actual Enrollment :

789 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase III Prospective Randomized Comparison of Imatinib at a Dose of 400mg in Combination With Peg-Interferon-alpha2a (Peg-IFNa2a) or Cytarabine (Ara-C)Versus Imatinib at a Dose of 600mg Versus Imatinib a Dose of 400mg for Previously Untreated Chronic Myelogenous Leukemia (CML) in Chronic Phase

Study Start Date :

Sep 1, 2003

Actual Primary Completion Date :

Dec 1, 2014

Actual Study Completion Date :

Dec 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Imatinib mesylate 400 mg	Drug: Imatinib mesylate 400 mg Drug: Imatinib mesylate 600 mg Drug: Imatinib 400 mg + Peg-Interferon Drug: Imatinib mesylate 400 mg + Cytarabine
Experimental: Imatinib mesylate 600 mg	Drug: Imatinib mesylate 400 mg Drug: Imatinib mesylate 600 mg Drug: Imatinib 400 mg + Peg-Interferon Drug: Imatinib mesylate 400 mg + Cytarabine
Experimental: Imatinib mesylate 400 mg +Peg interferon	Drug: Imatinib mesylate 400 mg Drug: Imatinib mesylate 600 mg Drug: Imatinib 400 mg + Peg-Interferon Drug: Imatinib mesylate 400 mg + Cytarabine
Experimental: Imatinib mesylate 400 mg +Cytarabine	Drug: Imatinib mesylate 400 mg Drug: Imatinib mesylate 600 mg Drug: Imatinib 400 mg + Peg-Interferon Drug: Imatinib mesylate 400 mg + Cytarabine

Outcome Measures

Primary Outcome Measures

Overall survival improvement []

Secondary Outcome Measures

Molecular response improvement at 1 year [1 year]
Hematological, cytogenetic responses improvement [1 year]
Duration of responses improvement []
Survival without progression improvement []
Acceptable toxicity []

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients over 18 years of age
Patients with Bcr-Abl positive CML in chronic phase.
Patients within 14 weeks of diagnosis and previously untreated for CML except for hydroxyurea and/or anagrelide.
No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly
ECOG performance score of 0-2
acceptable hepatic, renal, and cardiac function
Informed consent signed up

Exclusion Criteria:

Depressive syndrome not controlled
Uncontrolled medical illnesses.
Women with childbearing potential and male patients who are unwilling or unable to use an adequate method to avoid pregancy for the entire period of the study